Clinical trials: Refractory Epilepsy, open to volunteers
- Condition Refractory Epilepsy
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Tuberous Sclerosis Complex (TSC)
Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC)
1. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2.
- Trial name
- Spectrum (NCT07403266)
- Testing
- YCJ-01 Full Spectrum cannbis Extract
- Where
- Spain
- Volunteers
- 84 people
- Sponsor
- Oils4Cure
Mesial Temporal Lobe Epilepsy
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
The main goals of this clinical study are to learn if AMT-260 is safe and tolerable and works to reduce the frequency of seizures in adults with unilateral mesial temporal lobe epilepsy (MTLE).
- Trial name
- GenTLE (NCT06063850)
- Testing
- AAV9-hSyn1-miGRIK2
- Where
- 18 sites in United States
- Volunteers
- 12 people
- Sponsor
- UniQure Biopharma B.V.
Drug-Resistant Epilepsy
Clinical Trial of SEEG for Drug-resistant Epilepsy
This trial evaluates the safety and efficacy of SEEG recording and functional mapping for patients with drug-resistant epilepsy.
- Trial name
- SEEG-DRE (NCT07923058)
- Testing
- SEEG RF-TC
- Where
- 17 sites in China
- Volunteers
- 99 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Epilepsy (Treatment Refractory)
Translational Recording and Characterization of Epilepsy Signals Using Subgaleal EEG During Standard-of-care SEEG Monitoring
TRACE is a record-only study evaluating subgaleal EEG (sgEEG) recorded concurrently with standard-of-care stereoelectroencephalography (SEEG) in adults with drug-resistant epilepsy undergoing inpatient epilepsy monitoring.
- Trial name
- TRCE (NCT07821697)
- Testing
- EEG Record only
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Adraxe Corp.
Drug Resistant Epilepsy, Autism Spectrum Disorder
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or metabolic conditions requiring KD.
- Conditions
- Drug Resistant Epilepsy, Autism Spectrum Disorder, Chronic Migraine, Brain Tumor, Pediatric
- Trial name
- NCT06309251
- Testing
- ketogenic diet (as per clinical practice)
- Where
- 3 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Danone Nutricia SpA Società Benefit
Epilepsy, Temporal Lobe
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
This is a multicenter, single arm, open label clinical trial that is designed to test the safety and preliminary efficacy of single administration inhibitory nerve cells called interneurons (NRTX-1001), into both temporal lobes…
- Trial name
- NCT06422923
- Testing
- NRTX-1001
- Where
- 17 sites in United States
- Volunteers
- 10 people
- Sponsor
- Neurona Therapeutics
Drug Resistant Epilepsy, Refractory Epilepsy
Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for Epilepsy
This is a multi-site registry study that aims to collect real-world clinical outcomes and device performance of the OneRF Ablation System.
- Trial name
- NCT07546253
- Testing
- Participants are not assigned an intervention as part of the study.
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- NeuroOne Medical Technologies Corporation
Focal Epilepsy, Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in…
- Conditions
- Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure
- Trial name
- NCT07219407
- Testing
- RAP-219
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Rapport Therapeutics Inc.
Drug Resistant Epilepsy, Epilepsy
A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy
This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in…
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Seizures, Focal, Seizure
- Trial name
- NCT06388707
- Testing
- NaviFUS System
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- NaviFUS Corporation
Epilepsy, Epilepsy (Treatment Refractory)
Diagnosing Epilepsy To EffeCT Change
The purpose of this research is to address the challenges of diagnosing and long-term management of epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who cannot use…
- Trial name
- DETECT (NCT07110337)
- Testing
- Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Where
- 23 sites in United States
- Volunteers
- 210 people
- Sponsor
- Epiminder America, Inc.
Epilepsy, Temporal Lobe, Drug Resistant Epilepsy
Evaluation of the NaviFUS System in Drug Resistant Epilepsy
Participants with drug-resistant epilepsy (DRE) enrolled in this study will receive focused ultrasound (FUS) treatment with the NaviFUS System, guided by the neuronavigation system to evaluate the safety and efficacy of using…
- Trial name
- NCT05947656
- Testing
- NaviFUS System
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Genovate-NaviFUS (Australia) Pty Ltd.
Drug Resistant Epilepsy, Epilepsy
A Pilot Study to Evaluate the Efficacy and Safety of NaviFUS™ System Neuromodulating Treatment for Patients With Drug Resistant Epilepsy
This will be a prospective, pilot, open-label, two-arm, parallel-group, randomized study to evaluate the efficacy and safety of low-intensity focused ultrasound (LIFU) neuromodulation using NaviFUS System in patients with…
- Conditions
- Drug Resistant Epilepsy, Epilepsy, Epilepsy, Temporal Lobe, Seizures, Focal
- Trial name
- NCT06492720
- Testing
- Focused ultrasound (FUS) treatment
- Where
- Taiwan
- Volunteers
- 16 people
- Sponsor
- NaviFUS Corporation
Tuberous Sclerosis Complex, Epilepsy
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
This Phase 2, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, and efficacy of oral AV078 in participants with refractory epilepsy due to tuberous sclerosis complex (TSC).
- Trial name
- RESTOR-1 (NCT07680322)
- Testing
- AV078
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- Aeovian Pharmaceuticals, Inc.
Epilepsy, Epilepsy (Treatment Refractory)
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
The purpose of this research is to address the challenges of correctly monitoring, managing, and diagnosing epilepsy in participants whose seizures are not well captured by standard electroencephalography (EEG) tests and who…
- Trial name
- DETECT LTFU (NCT07110454)
- Testing
- Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system)
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- Epiminder America, Inc.
Drug Resistant Epilepsy
Feasibility Study of the iVEAcare Neuromodulation System for the Treatment of Drug-Resistant Epilepsy
The purpose of this study is to assess the safety and performance of the iVEAcare Neuromodulation System for the treatment of drug-resistant epilepsy.
- Trial name
- iVEAcare-FS (NCT07640191)
- Testing
- iVEAcare Neuromodulation System
- Where
- 7 sites in Australia
- Volunteers
- 30 people
- Sponsor
- iVEAcare
Focal Epilepsy
Long-term Safety and Tolerability of BHV-7000
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
- Trial name
- NCT06443463
- Testing
- BHV-7000
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 660 people
- Sponsor
- Biohaven Therapeutics Ltd.